Evidence map›Paper›PMID 41718091›Full record

ArticleProteomes2026

Scout-Triggered Multiple Reaction Monitoring Enables Robust Quantification of Host Cell Proteins Across Bioprocess Matrices.

Julie Flecheux, Chloé Bardet, Laura Herment, Tanguy Fortin, Jérôme Lemoine

Abstract read
In one paragraph

Article in Proteomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Julie FlecheuxInstitut des Sciences Analytiques (ISA), UMR5280, Université Claude Bernard Lyon1, CNRS, 69100 Villeurbanne, France.ORCID 0009-0000-0921-0635
Chloé BardetANAQUANT, 69007 Lyon, France.ORCID 0009-0004-9446-0258
Laura HermentANAQUANT, 69007 Lyon, France.ORCID 0009-0000-2501-3578
Tanguy FortinANAQUANT, 69007 Lyon, France.
Jérôme LemoineInstitut des Sciences Analytiques (ISA), UMR5280, Université Claude Bernard Lyon1, CNRS, 69100 Villeurbanne, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHost cell proteins (HCPs) are process-related impurities that must be monitored in biopharmaceutical products due to their potential impact on product quality and patient safety. Targeted LC-MS/MS approaches such as multiple reaction monitoring (MRM) enable protein-specific HCP quantification but are difficult to apply in highly multiplexed assays because of retention time (RT) variability across complex bioprocess matrices.

methodsHere, we show that conventional RT-scheduled MRM workflows lack transferability when applied to heterogeneous drug substances and process intermediates. Using a targeted assay comprising 240 peptides corresponding to 97 CHO-derived HCPs, RT shifts of several minutes resulted in truncated chromatographic peaks and peptide signal loss, even when wide scheduling windows were used. To overcome this limitation, a scout-triggered MRM (st-MRM) acquisition strategy based on event-driven monitoring was implemented.

resultsThis approach enabled robust peptide detection across diverse matrices within a single injection, without method re-optimization. Absolute quantification using stable isotope-labeled peptides spanned six orders of magnitude, with HCPs quantified down to 2.9 ppm in purified drug substances.

conclusionOverall, st-MRM improves the robustness and transferability of highly multiplexed targeted proteomics workflows for HCP analysis.

Indexed as

antibody(s) (mAbs)bioprocess developmenthost cell protein (HCP)liquid chromatography-mass spectrometry (LC-MS)multiple reaction monitoring (MRM)proteomic

Identifiers

PMID41718091
PMCPMC12921893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.